Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several animal studies of ILIT have been conducted in the form of translational or veterinary research. We conducted a literature review to examine the treatment efficacy and adverse effects of ILIT.
Animals ; Humans ; Hypersensitivity ; Immunotherapy ; Injections, Intralymphatic ; Sublingual Immunotherapy ; Treatment Outcome

OBJECTIVETo investigate the effect of activated charcoal-epirubicin suspension (Epi-CH) for treatment of breast cancer and clearance of axillary lymph node metastasis.

METHODSSixty patients with breast cancer of stages II-III were randomized into Epi-CH group (n=40) receiving injection with 10 mg Epi-CH in the tissue around the primary tumor 72 h before modified radical resection and control group (n=20) with 10 mg of aqueous epirubicin injection in the same region. The dissected axillary lymph nodes and the staining lymph nodes were counted. The concentration of epirubicin in the lymph nodes was detected by high-performance liquid chorography, and the specimens of lymph nodes were observed microscopically.

RESULTSIn comparison with the control group, Epi-CH injection allowed dissection of 4.04 more lymph nodes (P<0.01) and resulted in the staining rate of the axillary lymph nodes of 86.9% (565/650). The proportion of the staining lymph nodes with diameter>1.0 cm was significantly lower than that with diameter 0.05). In Epi-CH group, the concentration of epirubicin in the stained lymph nodes was significantly higher than that in non-stained ones (443.0-/+123.1 vs 31.8-/+11.9 ng/g, P<0.01). Remarkable degeneration and necrosis could be observed microscopically in the stained lymph nodes.

CONCLUSIONEpi-CH allows more effective treatment of breast cancer and clearance of axiliary metastasis by increasing the dissected lymph nodes and raising the concentration of epirubicin in the axillary lymph nodes.

Adult ; Aged ; Antibiotics, Antineoplastic ; administration & dosage ; Axilla ; Breast Neoplasms ; drug therapy ; pathology ; surgery ; Carcinoma, Ductal, Breast ; drug therapy ; pathology ; surgery ; Charcoal ; administration & dosage ; Epirubicin ; administration & dosage ; Female ; Humans ; Injections, Intralymphatic ; Lymph Nodes ; drug effects ; pathology ; Lymphatic Metastasis ; Middle Aged

OBJECTIVETo prepare anticancer nanoparticles for targeting therapy for oral cancer lymph node metastasis.

METHODSThe activated carbon nanoparticles (CH-NP) were prepared for drug carrier. Pingyangmycin (PYM), a high sensitive anticancer drug for oral squamous cell carcinoma, were selected as model drug. The activated carbon nanoparticles and PYM were mixed with saline and shaken 20 minutes so that PYM was absorbed on activated carbon enough, resulting in a new formulation of PYM (PYM-CH-NP). The absorbency of PYM on activated carbon nanoparticles was evaluated.

RESULTSThe diameter distribution for CH-NP ranged form 136 nm, to 540 nm, the average diameter was 176 nm. The proportion of CH-NP to PYM was increased and more absorbency of PYM on activated carbon nanoparticles was achieved.

CONCLUSIONThe activated carbon nanoparticles has high absorbency of PYM. The new formulation PYM-CH-NP can be used as targeting therapy of cervical lymph node metastasis by peri-cancer submucosal injection.

Antibiotics, Antineoplastic ; administration & dosage ; pharmacokinetics ; Bleomycin ; administration & dosage ; analogs & derivatives ; pharmacokinetics ; Carbon ; chemistry ; Carcinoma, Squamous Cell ; drug therapy ; secondary ; Humans ; Injections, Intralymphatic ; Lymph Nodes ; drug effects ; pathology ; Lymphatic Metastasis ; Mouth Neoplasms ; drug therapy ; pathology ; Nanoparticles ; Neck